ClinicalTrials.gg
CompletedNCT04030169Updated Jan 28, 2025Results posted

Open Label Study of MDMA-assisted Psychotherapy for Treatment of PTSD With Optional fMRI Sub-Study

A Phase 2 interventional study of Midomafetamine HCl in PTSD, sponsored by MAPS Europe B.V.. Completed at 6 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-01-28.

Sponsored by MAPS Europe B.V. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
21
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 38 studies testing N-Methyl-3,4-methylenedioxyamphetamine in Stress Disorders, Post-Traumatic — 11 open to participants now, 12 under way, 1 of them phase 3. N-Methyl-3,4-methylenedioxyamphetamine · Stress Disorders, Post-Traumatic.

Enrollment
23rd of 38
21 · median 25
Started
2020
with 1 other
Phase 2
28 of 38
10 open now
Registered
15th of 38
by date
Lead sponsor
1 of 38
MAPS Europe B.V.

Among the 38 studies testing N-Methyl-3,4-methylenedioxyamphetamine in Stress Disorders, Post-Traumatic, this one is the 23rd largest by enrollment, is one of 2 that started in 2020, is one of 28 in phase 2, and was the 15th registered.

Stress Disorders, Post-Traumatic

2,688 studies on the registry are indexed under Stress Disorders, Post-Traumatic; 606 are open to participants now.

Browse Stress Disorders, Post-Traumatic studies →

Open to participants now

11 of the 38 studies testing N-Methyl-3,4-methylenedioxyamphetamine in Stress Disorders, Post-Traumatic are open now, in 3 countries. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 11 open studies →

About N-Methyl-3,4-methylenedioxyamphetamine

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 417 Stress Disorders, Post-Traumatic studies recruiting now, 187 (45%) set no upper age limit and 204 (49%) stop at 75 or younger; 63 take children under 18; 89 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 38 studies testing N-Methyl-3,4-methylenedioxyamphetamine in Stress Disorders, Post-Traumatic, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if MDMA-assisted therapy is safe and effective in people diagnosed with at least severe PTSD.

The main question it aims to answer is: Do two open-label sessions of MDMA-assisted therapy reduce PTSD symptoms?

Participants will receive three non-drug preparatory sessions followed by two sessions of MDMA-assisted therapy. Each MDMA-assisted therapy session is followed by three non-drug integrative therapy sessions.

Read the detailed description

This multi-site, open-label, Phase 2, lead-in study conducted in Europe assesses the safety and efficacy of MDMA-assisted therapy in participants diagnosed with at least severe posttraumatic stress disorder (PTSD). This study additionally provides an opportunity for clinical supervision to planned Phase 3 therapy teams. Select sites will also participate in an optional fMRI (brain imaging) sub-study.

This study compares the effects of two open-label manualized Experimental Sessions of psychotherapy assisted by flexible doses of MDMA HCl. Initial doses per Experimental Session include 80 mg or 120 mg of MDMA HCl, followed 1.5 to 2 hours later by a supplemental half-dose (40 mg or 60 mg). Total amounts of MDMA to be administered per Experimental Session range from 80 mg to 180 mg. This \~8-week Treatment Period is preceded by three non-drug Preparatory Sessions. During the Treatment Period, each Experimental Session is followed by three Integrative Sessions of non-drug psychotherapy.

The primary endpoint is the change in Clinician Administered PTSD Scale for DSM 5 (CAPS-5) from Baseline to 13 weeks post-baseline (Visit 14). The secondary endpoint is the change in Sheehan Disability Scale (adapted SDS) item scores from Baseline to 13 weeks post-baseline (Visit 14).

03

Conditions studied

  • PTSD

Keywords

  • MDMA
  • methylenedioxymethamphetamine
  • psychotherapy
  • PTSD
  • Posttraumatic Stress Disorder
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Are at least 18 years old
  2. Are fluent in speaking and reading the predominantly used or recognized language of the study site
  3. Are able to swallow pills
  4. Agree to have study visits video-recorded, including Experimental Sessions, Independent Rater assessments, and non-drug psychotherapy sessions
  5. Must provide a contact (relative, spouse, close friend or other support person) who is willing and able to be reached by the investigators in the event of a participant becoming suicidal or unreachable
  6. Must agree to inform the investigators within 48 hours of any medical treatments and procedures
  7. People able to become pregnant (PABP) (i.e., assigned female at birth, fertile, following menarche and until becoming unless permanently sterile), must have a highly sensitive negative pregnancy test at study entry and prior to each Experimental Session, and must agree to use adequate through 10 days after the last Experimental Session. Adequate birth control methods include intrauterine device (IUD), injected or implanted hormonal methods, abstinence, oral hormones plus a barrier contraception, vasectomized sole partner.
  8. Agree to the following lifestyle modifications: comply with requirements for fasting and refraining from certain medications prior to Experimental Sessions, not enroll in any other interventional clinical trials during the duration of the study, remain overnight at the study site after each Experimental Session and be driven home after, and commit to medication dosing, therapy, and study procedures

Exclusion criteria

Exclusion Criteria:

  1. Are not able to give adequate
  2. Have any current problem which, in the opinion of the investigator or Medical Monitor, might interfere with participation
  3. Would present a serious risk to others as established through clinical interview and contact with treating psychiatrist
  4. Require ongoing concomitant therapy with a psychiatric medication (exceptions apply)
  5. Weigh less than 48 kilograms (kg)
  6. Are pregnant or nursing or are able to become pregnant and are not practicing an effective means of .
  7. Have a history of any medical condition that could make receiving a sympathomimetic drug harmful because of increases in blood pressure (BP) and heart rate.
  8. Have current alcohol or substance use disorder.
  9. Have used Ecstasy (material represented as containing MDMA) more than 10 times within the last 10 years or at least once within 6 months of the first Experimental Session; or have previously participated in a clinical trial conducted by the sponsor.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
21 participants (actual)

Study arms

  • Experimental
    Experimental: MDMA-assisted psychotherapy

    Administration of 80 to 120 mg midomafetamine (MDMA) HCl followed by a supplemental half-dose 1.5 to 2 hrs after the initial dose of 40 or 60 mg, respectively, in combination with manualized psychotherapy.

    Drug: Midomafetamine HCl

Interventions

  • Non-directive psychotherapy conducted during MDMA-assisted psychotherapy session

    Also known as: 3,4-methylenedioxymethamphetamine, MDMA, MDMA HCl, Midomafetamine

06

What researchers measure

Primary outcomes

  1. Change in CAPS-5 Total Severity Score

    The Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) is a 30-item semi-structured interview assessing PTSD in the past month through diagnostic and symptom severity scores anchored to a DSM-5 defined traumatic event. The CAPS-5 produces a Total Severity Score based on severity of PTSD domains described in the DSM-5, as well as a categorical rating indicating whether a participant meets PTSD diagnostic criteria. CAPS-5 Total Symptom Severity scores range from 0 to 80 with higher values designating greater symptom severity. CAPS-5 assigns PTSD diagnosis as being present or absent.

    Time frame: 13 weeks post-baseline

Secondary outcomes

  1. Change in Sheehan Disability Scale (SDS) Item Scores

    The Sheehan Disability Scale (SDS) is a clinician-rated assessment of functional impairment for PTSD. The SDS is a 3-item scale measuring the severity of disability (i.e., the degree of impairment) in the domains of work, family life/home responsibilities and social/leisure activities. Responses are recorded using an 11-point scale (0 = not at all to 10 = extremely) and 5 verbal tags (not at all, mildly, moderately, markedly, extremely). For participants who are not able to work for reasons unrelated to PTSD, the measure includes an option to skip the work-related impairment item, and the reason was collected. The impact of missing item-level data was mitigated by averaging across the items to obtain a Total Score, rather than a straight sum.

    Time frame: 13 weeks post-baseline

07

Results

Posted Jan 28, 2025

Participant flow

Participant flow — Overall Study
MilestoneMDMA-assisted Psychotherapy
Started21
Completed20
Not completed1

Outcome measures

PrimaryChange in CAPS-5 Total Severity Score

The Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) is a 30-item semi-structured interview assessing PTSD in the past month through diagnostic and symptom severity scores anchored to a DSM-5 defined traumatic event. The CAPS-5 produces a Total Severity Score based on severity of PTSD domains described in the DSM-5, as well as a categorical rating indicating whether a participant meets PTSD diagnostic criteria. CAPS-5 Total Symptom Severity scores range from 0 to 80 with higher values designating greater symptom severity. CAPS-5 assigns PTSD diagnosis as being present or absent.

Time frame:
13 weeks post-baseline
Reported as:
Least squares mean · score on a scale
Change in CAPS-5 Total Severity Score
score on a scaleMDMA-assisted Psychotherapy
Change in CAPS-5 Total Severity Score-13.95 (-16.32 to -11.58)
SecondaryChange in Sheehan Disability Scale (SDS) Item Scores

The Sheehan Disability Scale (SDS) is a clinician-rated assessment of functional impairment for PTSD. The SDS is a 3-item scale measuring the severity of disability (i.e., the degree of impairment) in the domains of work, family life/home responsibilities and social/leisure activities. Responses are recorded using an 11-point scale (0 = not at all to 10 = extremely) and 5 verbal tags (not at all, mildly, moderately, markedly, extremely). For participants who are not able to work for reasons unrelated to PTSD, the measure includes an option to skip the work-related impairment item, and the reason was collected. The impact of missing item-level data was mitigated by averaging across the items to obtain a Total Score, rather than a straight sum.

Time frame:
13 weeks post-baseline
Reported as:
Least squares mean · Score on a scale
Change in Sheehan Disability Scale (SDS) Item Scores
Score on a scaleExperimental: MDMA-assisted Psychotherapy
Family Life / Home-1.18 (-2.14 to -0.22)
Social / Leisure Activities-1.45 (-2.32 to -0.58)
Work / School-1.45 (-2.36 to -0.53)
Total Score-1.30 (-2.17 to -0.43)

Adverse events

Collected over Approximately 8 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Experimental: MDMA-assisted Psychotherapy0/21 (0%)2/21 (9.5%)21/21 (100%)
Most frequent serious events
Most frequent serious events
EventExperimental: MDMA-assisted Psychotherapy
Suicidal ideationPsychiatric disorders1/21
Suicidal behaviorPsychiatric disorders1/21
Most frequent other events
Showing 10 of 21
Most frequent other events
EventExperimental: MDMA-assisted Psychotherapy
HeadacheNervous system disorders15/21
NauseaGastrointestinal disorders8/21
Muscle tightnessMusculoskeletal and connective tissue disorders8/21
Suicidal ideationPsychiatric disorders7/21
FatigueGeneral disorders4/21
Decreased appetiteMetabolism and nutrition disorders4/21
InsomniaPsychiatric disorders4/21
MyalgiaMusculoskeletal and connective tissue disorders3/21
AnxietyPsychiatric disorders3/21
PalpitationsCardiac disorders2/21

Baseline characteristics

Age, Continuous
Age, Continuous(Years)MDMA-assisted Psychotherapy
Mean44.3 ± 10.15
Sex: Female, Male
Sex: Female, Male(Participants)MDMA-assisted Psychotherapy
Female11
Male10
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)MDMA-assisted Psychotherapy
Hispanic or Latino0
Not Hispanic or Latino21
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)MDMA-assisted Psychotherapy
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American1
White20
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)MDMA-assisted Psychotherapy
Netherlands8
Czechia3
Norway2
United Kingdom6
Germany2
08

Study locations

6 sites
  • NUDZ - National Institute of Mental Health
    Klecany, Středočeský Kraj 250 67, Czechia
  • Charité - Universitätsmedizin, Berlin Campus Benjamin Franklin
    Berlin, 12203, Germany
  • Stichting Centrum '45/Arq
    Oegstgeest, Noord Holand 2342 AX, Netherlands
  • Sykehuset Østfold Hf, DPS Norder
    Moss, 1535, Norway
  • University Hospital of Wales - Research Facility
    Cardiff, CF14 4XW, United Kingdom
  • The Institute of Psychiatry, Psychology and Neuroscience
    London, SE5 8AF, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — We will share outcome data appearing in any published reports upn request.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Data and study-related documents will be available when all participants have completed the study.

Access criteria: Interested persons should correspond with the central contact for the multi-site study.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2020 to primary completion in Dec 2023, 41 months.

Results were first posted in Jan 2025, 1 year 1 month after primary completion.

Of 31 industry-sponsored phase 2 interventional studies under Stress Disorders, Post-Traumatic, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 33. This study's 41 months is above that.

Counting every sponsor, half of 118 studies reached it within 38 months; a quarter within 23 and three quarters within 53.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 19, 2019
First posted
Jul 23, 2019
StartActual
Jun 24, 2020
Primary completionActual
Dec 14, 2023
CompletionActual
Dec 15, 2023
Results first posted
Jan 28, 2025
Last update
Jan 28, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 28, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04030169
Lead sponsor
MAPS Europe B.V.
Collaborators
Multidisciplinary Association for Psychedelic Studies
Responsible party
Sponsor
First posted
Jul 23, 2019
Start date
Jun 24, 2020
Primary completion
Dec 14, 2023
Completion
Dec 15, 2023
Results posted
Jan 28, 2025
Last update
Jan 28, 2025

Study contacts

Prof. Dr. Eric Vermetten, MD
principal investigator · Leiden University Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: N-Methyl-3,4-methylenedioxyamphetamine

Start the discussion